Muntau, A. C. Et Al. 2017. Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients < 4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial. ORPHANET JOURNAL OF RARE DISEASES , vol.12 .

Muntau, A. C., Burlina, A., Eyskens, F., Freisinger, P., De Laet, C., Leuzzi, V., ... Rutsch, F.(2017). Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients < 4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial. ORPHANET JOURNAL OF RARE DISEASES , vol.12.

Muntau, Ania Et Al. "Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients < 4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial," ORPHANET JOURNAL OF RARE DISEASES , vol.12, 2017

Muntau, Ania C. Et Al. "Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients < 4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial." ORPHANET JOURNAL OF RARE DISEASES , vol.12, 2017

Muntau, A. C. Et Al. (2017) . "Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients < 4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial." ORPHANET JOURNAL OF RARE DISEASES , vol.12.

@article{article, author={Ania C. Muntau Et Al. }, title={Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients < 4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial}, journal={ORPHANET JOURNAL OF RARE DISEASES}, year=2017}